LP-184 by Starlight Therapeutics for Melanoma: Likelihood of Approval

LP-184 is under clinical development by Starlight Therapeutics and currently in Phase I for Melanoma.

As 23andMe struggles, another genetic testing company bets on drug discovery

Two years ago, GeneDx was teetering. The genetic testing company had laid off 33% of its staff, shares were down 90% from a year prior

December 5, 2024

Regular exercise can improve cognitive and physical, health of adults with Down syndrome

An exploratory study has shown that light, regular exercise can improve the cognitive, as well as physical, health of adults with Down syndrome.

November 30, 2023

Cybin to Present at Public Ventures Discovery Day on March 19th in Dallas | Psychedelic Invest

Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based

March 18, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.